바이오노트

바이오노트 discloses dealings in 2 companies, chiefly 유바이오로직스 and 바이오노트. We count 61 filings; the first trade dates from 26 February 2021 and the latest from 2 April 2026.

Purchases make up the whole of the open-market record (56 purchases, €2.8M). The totals exclude 53 filings filed without an amount. Unlike grants, an open-market purchase is paid for by the insider, at the market price. 2026 to date brings 4 purchases and no sales.

The median purchase comes to €704k. As a share of market capitalisation, the median purchase stands at 0.36%, based on 3 purchases. The 56 purchases reviewed show no overlap with other insiders buying the same stock within a month. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 0% of cases, with a median move of -36.3%. They describe history only and say nothing certain about the share price ahead.

The latest filing, published on 7 April 2026, reports an open-market purchase of €704k in 유바이오로직스. Filings reach the DART (FSS) feed a median of 7 days after the trade. The shorter that gap, the sooner other investors can see what insiders have done. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.